Title:
ウレア誘導体、またはその薬理学的に許容される塩
Document Type and Number:
Japanese Patent JP6746614
Kind Code:
B2
Abstract:
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
More Like This:
Inventors:
Yuho Takahashi
Hiroyuki Watanabe
Kiyoshi Fujii
Mitsuto Shibasaki
Kawashima Mikako
Megumi Kamiya
Kohei Ohata
Hiroyuki Watanabe
Kiyoshi Fujii
Mitsuto Shibasaki
Kawashima Mikako
Megumi Kamiya
Kohei Ohata
Application Number:
JP2017560633A
Publication Date:
August 26, 2020
Filing Date:
May 26, 2016
Export Citation:
Assignee:
Kyorin Pharmaceutical Co., Ltd.
International Classes:
C07D231/12; A61K31/17; A61K31/275; A61K31/343; A61K31/366; A61K31/381; A61K31/41; A61K31/415; A61K31/4192; A61K31/4196; A61K31/42; A61K31/421; A61K31/422; A61K31/4245; A61K31/426; A61K31/433; A61K31/44; A61K31/454; A61K31/506; A61K31/5377; A61K31/5395; A61P9/00; A61P11/00; A61P25/00; A61P25/04; A61P25/28; A61P29/00; A61P29/02; A61P31/04; A61P31/18; A61P35/00; A61P37/02; A61P37/08; A61P39/02; C07C275/30; C07C317/28; C07D239/36; C07D249/04; C07D249/08; C07D249/12; C07D257/04; C07D261/08; C07D263/32; C07D263/34; C07D271/06; C07D271/07; C07D271/10; C07D271/113; C07D273/04; C07D277/28; C07D285/08; C07D285/12; C07D405/06; C07D413/04
Foreign References:
| WO2013070600A1 | ||||
| WO2004007459A1 | ||||
| WO2015035051A1 | ||||
| WO2007076055A1 | ||||
| WO2015019325A1 | ||||
| WO1999064401A1 | ||||
| WO2008002570A1 | ||||
| WO2000031063A1 |
Other References:
Journal of Organic Chemistry,1959年,Vol.24,pp.1643-1649
Database REGISTRY,2011年,RN 1327895-99-7, 1328412-07-2, 1328901-17-2, Retrieved from STN international [online] ;retrieved on 1 April 2020
Journal of Medicinal Chemistry,2009年,Vol.52,pp.5044-5057
Bioorganic & Medicinal Chemistry Letters,2005年,Vol.15,pp.4862-4866
Molecular Pharmacology,2010年,Vol.77,pp.159-170
Database REGISTRY,2011年,RN 1327895-99-7, 1328412-07-2, 1328901-17-2, Retrieved from STN international [online] ;retrieved on 1 April 2020
Journal of Medicinal Chemistry,2009年,Vol.52,pp.5044-5057
Bioorganic & Medicinal Chemistry Letters,2005年,Vol.15,pp.4862-4866
Molecular Pharmacology,2010年,Vol.77,pp.159-170
Attorney, Agent or Firm:
Samejima Mutsumi
Nagatoshi Shinagawa
Kure Hidenori
Kamahira Futami
Mizuhara Masahiro
Nagatoshi Shinagawa
Kure Hidenori
Kamahira Futami
Mizuhara Masahiro